• Français
  • Search
  • Conference
    • CAHR 2023
    • Future CAHR Conferences
    • Mark Wainberg Lecture
    • Past Conferences
  • Awards
    • HCP Travel Awards Competition
    • Mark Wainberg Fund
    • CAHR-CANFAR Excellence in Research Awards
    • Red Ribbon Award
    • Funding Archive
    • Funding Landscape
  • Training
    • Workshops
    • Webinars
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada PART 2
    • Clinical Summaries
    • E-Learning Modules
    • Posters and Presentations
    • Community Based Research
    • Student Profiles
    • Training Workshops: Consultation Report
    • Publications / Resources
  • About CAHR
    • Who We Are
    • President’s Message
    • Board of Directors
    • Become a Member
    • CAHR Annual General Meeting
    • CAHR Strategic Plan 2020 – 2025
    • Staff
    • Contact
  • Media
    • CAHR News
    • Media
    • Featured Researchers
  • Conference
    • CAHR 2023
    • Future CAHR Conferences
    • Sponsors & Exhibitors
    • Mark Wainberg Lecture
    • Past Conferences
  • Awards
    • HCP Travel Awards Competition
    • Mark Wainberg Fund
    • CAHR-CANFAR Excellence in Research Awards
    • Red Ribbon Award
    • Funding Archive
    • Funding Landscape
  • Training
    • Workshops
    • Webinars
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada PART 2
    • Clinical Summaries
    • E-Learning Modules
    • Posters and Presentations
    • Community Based Research
    • Student Profiles
    • Training Workshops: Consultation Report
    • Publications / Resources
  • About CAHR
    • Who We Are
    • President’s Message
    • Board of Directors
    • CAHR Board Trainee
    • Become a Member
    • CAHR Strategic Plan 2020 – 2025
    • CAHR Annual General Meeting
    • Call for Nominations: CAHR Board of Directors
    • Staff
    • Contact
  • Media
    • CAHR News
    • Media

Dr. Jean-Pierre Routy

The Immune System and the Cure for HIV
McGill University and Royal Victoria Hospital, Montréal

HIV/AIDS was an little known disease when Dr. Jean-Pierre Routy was in his residency at Centre Hospitalier Général d’Aix-en-Provence in 1982. “Within 15 days of starting my residency, I got a call about a young patient, he was 26 years old, had seizures, a brain lymphoma and atypical tuberculosis. I was facing a mystery,” says Dr. Routy. He couldn’t help but feel a kinship with this young man. As the world became aware of AIDS, Dr. Routy knew that this patient was likely suffering from this disease. But at the time, little could be done and the patient died soon after. This patient and that moment in time oriented Dr. Routy’s career towards HIV research and treatment.

Today, Dr. Routy’s work focuses on immune-based therapies and therapeutic vaccines that modify or enhance the role of the patient’s immune system in fighting HIV infection. “The body wants to protect itself and creates an anti-inflammatory response to control organ damage induced by the virus, but in the absence of a cure, the system continues and the fight back may be worse than the invader,” explains Dr. Routy. “Immune-based therapies represent a new era in HIV treatment.”

Supported by the CIHR HIV/AIDS Research Initiative as part of a team of researchers across Canada, Dr. Routy recently explored the use of Interleukin-7 (IL-7), a cytokine that promotes T-cell growth. The team of researchers looked at IL-7 in the context of gut mucosa, a permeable surface that becomes increasingly so during HIV infection. This ‘leaky gut’ allows microbes to leak through the mucosa which in turn causes chronic immune activation in the body. The clinical study of HIV+ patients showed that treatment with IL-7 increased CD4+ cell expansion in the blood and decreased inflammation in the gut. It was also able to partially repair the gut by increasing the number of CD4+ T cells.

Of course, research into this new line of treatment is not without its challenges and negative results are part of progress. Dr. Routy and his colleagues recently published a paper on the use of chloroquine for promoting CD4+ T cell recovery by reducing inflammation. Chloroquine is used in other autoimmune disorders and would be an ideal medication because of its low cost and good safety profile. But, the results have been negative, showing no change in CD4+ T-cell recovery in clinical trials. “It’s a bit disappointing,” Dr. Routy admits, “but at least we’ve answered the question.

As part of the Canadian HIV Cure Enterprise Team (CanCURE) supported by CIHR, CANFAR and the International AIDS Society, Dr. Routy’s research continues to venture into novel treatment strategies. He hopes these new treatments will help to eliminate HIV from the body by making the virus more visible to the immune system. In this new era of HIV therapeutics, “We have to think differently,” says Dr. Routy.

The Canadian Association for HIV Research (CAHR), the CIHR HIV/AIDS Research Initiative, the Canadian Foundation for AIDS Research (CANFAR), the CIHR Canadian HIV Trials Network (CTN) and the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) would like to thank Dr. Routy and his colleagues for their significant contributions to our understanding of HIV. Their work is part of a larger Canadian research effort that is making a difference in the lives of those affected by HIV in Canada and around the world.

Our Mission

  • Promote excellence in HIV research
  • Foster collaboration and cooperation among HIV research communities, including basic science, clinical science, epidemiology & public health and social science
  • Promote education and the development of new researchers
  • Provide a unified voice for Canadian HIV researchers and engage diverse stakeholders (community, industry, Government, NGO’s etc.) in ongoing dialogue and knowledge exchange to ensure that HIV research remains responsive to their needs
CAHR 2023 Conference Logo

CAHR 2023
April 27 to 30, 2023

Learn More

Recent News

  • #CAHR2023 - Ancillary Events / #ACRV2023 - Événements connexes myemail.constantcontact.com/CAHR-2023---An…
  • CAHR extends its thanks to all Sponsors of the CAHR 2023 Conference. Learn more on our website, or visit them in the exhibit hall at the conference : cahr-acrv.ca/conference/spo… #CAHR2023 https://t.co/xEI7YTmvUB
  • L'ACRV adresse ses remerciements à tous les commanditaires du congrès ACRV 2023. Vous en saurez plus à leur sujet en consultant notre site Web ou en leur rendant visite à la salle des exposants du congrès : cahr-acrv.ca/fr/congres/spo… qGwC #ACR https://t.co/XIPkTSSQ39
  • For those developing a CAHR 2023 poster or interested in refining your presenting skills, CAHR has an online tutorial that aims to provide you with tips to make your poster one to remember. Click here: rise.articulate.com/share/n61pMfDF… #CAHR2023
  • Cliquez ici : rise.articulate.com/share/wSF8uyi0… #ACRV2023 (2/2)
  • Résultats du concours de bourses de voyage pour professionnels de la santé – 2023
Subscribe to the CAHR Newsletter

About CAHR

With a membership of more than 1,000 researchers and others interested in HIV research, the Canadian Association for HIV Research (CAHR) is the leading organization of HIV/AIDS researchers in Canada. CAHR is the organizing body for the Annual Canadian Conference on HIV/AIDS Research (CAHR Conference).

CAHR encourages Canadian researchers to be leaders in knowledge translation and to effectively respond both to the Canadian and global HIV/AIDS epidemics. Since its founding in 1991, CAHR has promoted excellence in HIV research, including mentorship and career development of investigators entering the field.

CAHR fosters collaboration and co-operation among HIV research communities, including basic, clinical and social sciences, epidemiology and public health. CAHR also engages people living with HIV/AIDS and AIDS service organizations in ongoing dialogue and information exchange to ensure that HIV/AIDS research remains responsive to the epidemic and its stakeholders.

CAHR is a registered charity.

Links

  • Who We Are
  • Conference
  • Awards
  • Workshops
  • Featured Researchers
  • Student Profiles
  • CAHR News

Contact

For more information or to make a comment, please contact us:

Canadian Association for HIV Research

440 Laurier Avenue West, Suite 200
Ottawa, Ontario K1R 7X6

1-888-374-CAHR (2247)
info@cahr-acrv.ca
  • Media
  • Contact
  • Français